Therapeutic implications of the kinetics of immunomodulation during singleor combined treatment of melanoma patients with dacarbazine and interferon-alpha

The therapy of metastatic melanoma has not given satisfactory results. Sing le chemo- or immunotherapeutic agents in the adjuvant setting or combined c hemoimmunotherapy for metastatic disease have generally been evaluated only in terms of clinical benefit. Considering that dacarbazine (DTIC) and inte rferon-alpha (IFN-alpha) are among the most frequently used agents in the t reatment of melanoma, the aim of this study was to evaluate the kinetics of immunological changes during adjuvant treatment of melanoma patients with DTIC or with IFN-alpha monotherapy, as well as by their combination in meta static disease. The evaluated immunological parameters showed significant e arly increase in the activity of NK (natural killer) cells, CD4/CD8 ratio, CD4(+) T cell number in patients treated with combined chemoimmunotherapy a nd an increase in expression of the early activation antigen CD38 on CD8(+) cytotoxic T cells, both, in patients treated with combined chemoimmunother apy and with IFN-alpha alone, while, no significant change in any one param eter was detected in the group of patients receiving DTIC. The kinetics of the observed immunological changes, restricted to combined chemoimmunothera py, indicate that the engagement of antitumor immune response appears early but is short-lived and that this favorable effect should be augmented and prolonged by the timely introduction of additional immunomodulating agents.